Loading…
Korean peptide-drug developer with a GLP-1/glucagon obesity and MASH pipeline, several candidates licensed to global partners.
Korean peptide-drug developer with a GLP-1/glucagon obesity and MASH pipeline, several candidates licensed to global partners.
Earns little from sales of its own; its value comes from licensing peptide candidates to bigger partners for upfront and milestone payments, and from equity stakes in those partners, notably Metsera, a US obesity-drug developer built partly on its licensed assets.
Moat: narrow (IP / patents). Peptide-delivery platform behind several GLP-1 obesity candidates already licensed to global partners.
Headquarters: Seoul, South Korea · Founded: 2014 · Employees: 22
Size D&D Pharmatech (347850.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.28B, the 199th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩37,750 on 6 Nov 2026.
Performance Over six months the shares fell 49.1%, against -10.9% for the median peer and -24.5% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 70.5% over the last twelve months (peer median +15.6%); the operating margin is -1,367.9% (peer median 2.8%).
Valuation It trades at 617.6× enterprise value to sales against a peer median of 5.0× (most expensive of 18).
Capital Return on invested capital runs 36.5 points below its cost of capital (7.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩2.75B | ₩4.30B | ₩11.4B | ₩18.7B | ₩611M |
| Revenue growth | — | -62% | -39% | +2,959% | — |
| Gross profit | -₩2.91B | -₩1.23B | ₩5.91B | ₩14.2B | -₩13.1B |
| EBITDA | -₩32.0B | -₩28.5B | -₩19.5B | -₩9.06B | -₩54.9B |
| Net income | -₩21.6B | -₩23.6B | -₩28.6B | ₩3.93B | -₩136B |
| Free cash flow | -₩24.9B | -₩21.2B | -₩22.2B | -₩9.16B | -₩53.8B |
| Capital expenditure | ₩41.3M | ₩64.4M | ₩416M | ₩45.2M | ₩719M |
| Total debt | ₩115B | ₩6.24B | ₩9.78B | ₩8.13B | ₩27.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| D&D Pharmatech 347850.KS | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a |
| HanmiPharm 128940.KS | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 347850.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.1% | -6.2% | 5th lowest of 21 |
| 6-month return | -49.1% | -10.9% | 4th lowest of 21 |
| Distance from 52-week high | -67.6% | -40.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | -70.5% | +15.6% | lowest of 17 |
| Operating margin | -1,367.9% | 2.8% | 2nd lowest of 18 |
| EV / Sales | 617.6× | 5.0× | most expensive of 18 |
| ROIC minus cost of capital | -36.5 pp | -5.1 pp | 6th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | 13.3× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 3.5× | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |